Results 31 to 40 of about 19,166 (184)

Thrombosis and paroxysmal nocturnal haemoglobinuria

Thrombosis Update, 2021
Thrombosis is the most common, most feared complication of paroxysmal nocturnal haemoglobinuria (PNH), a striking example of the effect of uncontrolled complement activation and haemolysis on vascular biology and haemostasis.
Jean-Christophe Gris, Mathias Chéa, Florence Guillotin, Mathieu Fortier, Chloé Bourguignon, Éric Mercier, Sylvie Bouvier   +6 more
doaj   +1 more source

Contribution of the infection-associated complement regulator-acquiring surface protein 4 (ErpC) to complement resistance of Borrelia burgdorferi [PDF]

, 2012
Borrelia burgdorferi evades complement-mediated killing by interacting with complement regulators through distinct complement regulator-acquiring surface proteins (CRASPs).
Teresia Hallström, Peter F. Zipfel, Zipfel, Peter F, Christine Skerka, Hallström, Teresia, Kraiczy, Peter, Skerka, Christine, Claudia Hammerschmidt, Wallich, Reinhard, Hammerschmidt, Claudia, Zipfel, Peter F., Reinhard Wallich, Peter Kraiczy, Stevenson, Brian, Brian Stevenson   +14 more
core   +1 more source

Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Haematologica, 2020
Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11%-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab.
Robert A. Brodsky, Régis Peffault de Latour, Scott T. Rottinghaus, Alexander Röth, Antonio M. Risitano, Ilene C. Weitz, Peter Hillmen, Jaroslaw P. Maciejewski, Jeff Szer, Jong Wook Lee, Austin G. Kulasekararaj, Lori Volles, Andrew I. Damokosh, Stephan Ortiz, Lori Shafner, Peng Liu, Anita Hill, Hubert Schrezenmeier   +17 more
doaj   +1 more source

How we (will) treat PNH?

Hematology, Transfusion and Cell Therapy, 2022
Clinical signs arising from intravascular hemolysis, hemolysis-related transfusions and thrombosis are indications for treatment initiation in paroxysmal nocturnal hemoglobinuria (PNH), whereas clone size per se is not.
Semra AYDIN
doaj   +1 more source

Paths reunited: initiation of the classical and lectin pathways of complement activation [PDF]

, 2010
Understanding the structural organisation and mode of action of the initiating complex of the classical pathway of complement activation (C1) has been a central goal in complement biology since its isolation almost 50 years ago.
Schmid, Ralf, Schwaeble, Wilhelm J., Wilhelm J. Schwaeble, Anthony H. Keeble, Russell Wallis, Mitchell, Daniel A., Keeble, Anthony H., Wallis, Russell, Ralf Schmid, Daniel A. Mitchell   +9 more
core   +1 more source

C3 Glomerulopathy and Therapeutic Potential of C5 Complement Inhibitors

Open Journal of Nephrology, 2016
C3 glomerulopathy is a disease including both dense deposit disease and C3 glomerulonephritis has an estimated prevalence of 2 to 3 per million. Originally, these pathologies were defined as glomerular pathology characterized by accumulation of C3 with absent or scanty immunoglobulin deposition.
Aysam Mahmoud, Zeeshan Sheikh, Safia Gilani, Paru Kathpalia   +3 more
openaire   +2 more sources

Application of the C3 inhibitor compstatin in a human whole blood model designed for complement research – 20 years of experience and future perspectives [PDF]

, 2022
The complex molecular and cellular biological systems that maintain host homeostasis undergo continuous crosstalk. Complement, a component of innate immunity, is one such system.
Lambris, John D., Storm, Benjamin S., Brekke, Ole Lars, Nilsson, Per H., Brekke, Ole L., Storm, Benjamin S.,, Mollnes, Tom E.,, Nilsson, Per H.,, Lambris, John D.,, Mollnes, Tom Eirik, Brekke, Ole L.,, Storm, Benjamin, Mollnes, Tom E.   +12 more
core   +1 more source

Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population

Frontiers in Immunology, 2018
Introduction: The complement system is essential for an adequate immune response. Much attention has been given to the role of complement in disease. However, to better understand complement in pathology, it is crucial to first analyze this system under ...
Mariana Gaya da Costa, Felix Poppelaars, Felix Poppelaars, Cees van Kooten, Tom E. Mollnes, Tom E. Mollnes, Tom E. Mollnes, Francesco Tedesco, Reinhard Würzner, Leendert A. Trouw, Leendert A. Trouw, Lennart Truedsson, Mohamed R. Daha, Mohamed R. Daha, Anja Roos, Marc A. Seelen   +15 more
doaj   +1 more source

Meningococcal Sepsis in Patient with Paroxysmal Nocturnal Hemoglobinuria during Pegcetacoplan Therapy

Emerging Infectious Diseases
Complement C5 inhibitors bring an increased risk for Neisseria infections. A novel complement C3 inhibitor, pegcetacoplan, was recently approved to treat paroxysmal nocturnal hemoglobinuria, a condition commonly treated with complement C5 inhibitors. We
Leo Starck, Vuokko Nummi, Eira Poikonen, Anna-Elina Lehtinen, Pia Kivelä, Nathalie Friberg, Jukka Torvikoski, Maija Toropainen, Seppo Meri   +8 more
doaj   +1 more source

A serine protease isolated from the bristles of the Amazonic caterpillar, Premolis semirufa, is a potent complement system activator. [PDF]

PLoS ONE, 2015
The caterpillar of the moth Premolis semirufa, commonly named pararama, is found in the Brazilian Amazon region. Accidental contact with the caterpillar bristles causes an intense itching sensation, followed by symptoms of an acute inflammation, which ...
Isadora Maria Villas Boas, Giselle Pidde-Queiroz, Fabio Carlos Magnoli, Rute M Gonçalves-de-Andrade, Carmen W van den Berg, Denise V Tambourgi   +5 more
doaj   +1 more source